In a statement, Senator Warren said: "This bill will make a life changing difference for the millions of Americans who experience hearing loss but can't access the care they need because of archaic regulations. I'm glad to work with Senator Paul on this common-sense step to bring down costs for our seniors.".Since that conversation inflation for certain items has jumped. In fact consumer price data indicate that the COLA for next year may be the highest since 2019, if the trends continue. My estimates about the COLA are based on the most current available data from the Bureau of Labor Statistics, for what it's worth..The assertion that many lower - income beneficiaries would lose benefits due to higher COLAs simply isn't the case, but is rather another example of twisted partisan rhetoric. Voters would be far better served by lawmakers who are more focused on solving problems of the majority of people than spreading misinformation to protect the tax breaks of the nation's wealthiest workers..An intense battle over Social Security is brewing and TSCL is gearing up for major Congressional action. Recently retired Federal Reserve Chairman Alan Greenspan waded back into the fray to tell Congress "Our choices right now are not between good and better; they're between bad and worse. The problem we now face is the most extraordinary financial crisis that I have ever seen or read about. Irrespective of what you say should be done on the tax side, you still have to cut some benefits on the expenditure side." The statement is chilling considering Greenspan oversaw the largest single overhaul of the program in history, chairing the National Commission on Social Security Reform in the early 1980's..Let me be clear: I value genuine research and development, I believe drug companies should be able to make reasonable profits, and I understand that investors expect reasonable returns. I also believe, however, that it is Congress' job to ensure that Americans do not have to live with the fear that they will go bankrupt if they get sick. That is why I introduced the Prescription Drug Affordability Act of 2015 with Senator Bernie Sanders last year. This bill is a bold and comprehensive approach to reducing prescription drug prices in the United States. It empowers the Secretary of Health and Human Services to negotiate drug prices under the Medicare Part D prescription drug program; it enhances transparency, encourages competition, and brings much needed accountability to the pharmaceutical industry..As originally introduced, the bill tied all income taxes paid on Social Security benefits to the Social Security Trust Fund, and none to the Medicare Trust Fund. Instead, the bill specified that revenues destined for the Medicare Trust Fund would come from general revenues, in an amount equal to those that the trust fund was otherwise estimated to receive from the taxation of Social Security benefits..Seventy - nine percent of older Americans think the highest -earning workers should be paying Social Security taxes on all of their wages, just like other workers do, according to recent survey by The Senior Citizens League. "The issue is a top priority with older voters, many of whom are outraged at recent legislative proposals to cut Social Security benefits and cost-of-living adjustments," says Mary Johnson, a Social Security policy analyst for TSCL..It required a mix of financial incentives, unprecedented world-wide need, and government prodding. But drug companies stepped up, and based on their performance in the stock market, they appear to be prospering. The federal government negotiated not only prices, but also it purchased hundreds of millions of doses of vaccines, made the vaccines available to the public at no charge, and has overseen the distribution of the vaccines to states. Those vaccines are saving lives, helping to get workers back on the job, and allowing those of us who are fully vaccinated to carefully start to resume pre-pandemic activities, such as visits with friends, family and grandchildren..The application was approved under Section 505 of the Federal Food, Drug and Cosmetic Act, which means that although it is a new drug application, its approval was based on research from another product.
